Business / Finance

RSS

MINDBODY offers cloud-based business management software to over 15,000 clients

MINDBODY clients saw an average increase of 22% in holiday gift giving for health and wellness services this year over the 2010 season, with over 2,300 gift cards purchased as last-minute gifts on Christmas Eve.

7 Jan 2012

OneMedForum San Francisco 2012 event to culminate with 'India Forum'

OneMedPlace today announced that its 5th annual "OneMedForum San Francisco 2012" event will culminate with the "India Forum" on the afternoon of January 11, 2012. The forum will examine how Western companies can capitalize in the booming India market.

7 Jan 2012

Gilead receives early termination of HSR waiting period for Pharmasset tender offer

Gilead Sciences, Inc. today announced that it has received early termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead's cash tender offer for Pharmasset, Inc.

7 Jan 2012

Cardium resolves continued listing deficiencies with NYSE Amex

Cardium Therapeutics today reported that it had received notice from NYSE Regulation that the Company is now considered to have regained compliance with the listing requirements of the NYSE Amex LLC.

7 Jan 2012

VirtualScopics receives NASDAQ Stock Market notice

VirtualScopics, Inc., a leading provider of image-based solutions to the pharmaceutical, biotechnology and medical device industries, announced today that on January 4, 2012 it received a notice from the NASDAQ Stock Market indicating that the Company's minimum bid price has fallen below $1.00 for 30 consecutive business days.

7 Jan 2012

Supernus secures $42M through two transactions

Supernus Pharmaceuticals, Inc. today announced that in December 2011 it closed two transactions through which it raised $42 million.

7 Jan 2012

Synta prices underwritten public offering of 7,000,000 shares of common stock

Synta Pharmaceuticals Corp. announced today that it has priced an underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $4.40 per share.

7 Jan 2012

GSN completes $20M financing round

Gene Security Network Inc. (GSN) today announced the completion of a $20 million financing round, as well as the change of the company's name to Natera, Inc. The financing round was led by Lightspeed Venture Partners, which is joined in the current round by Claremont Creek Ventures and Sequoia Capital.

7 Jan 2012

Third Security, Transgenomic enter Convertible Promissory Note Purchase Agreement

Transgenomic, Inc. today announced that it has entered into a Convertible Promissory Note Purchase Agreement in the aggregate amount of $3.0 million with entities associated with Third Security, LLC, a leading life sciences investment firm.

7 Jan 2012

Roka raises $47.5M in Series D round

Roka Bioscience announced today that it has secured $47.5 million in Series D financing. New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors, New Enterprise Associates, Inc., and TPG Biotech. In conjunction with the financing, Josh Bilenker, M.D., Partner at Aisling Capital, will join Roka's Board of Directors.

6 Jan 2012

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo Pharmaceuticals announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine.

6 Jan 2012

TrovaGene enters definitive agreement to acquire MultiGEN

TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has entered into a definitive agreement to acquire MultiGEN Diagnostics, Inc.'s clinical laboratory assets in exchange for the issuance of 750,000 shares of common stock of TrovaGene, with an additional earn-out of up to $3.7 million in cash and common stock, subject to the achievement of specific sales and earnings targets.

6 Jan 2012

PDL settles exchange offer, announces final results

PDL BioPharma, Inc. today announced the settlement and final results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2012 Convertible Senior Notes due 2015 (New Notes), and a cash payment.

6 Jan 2012

Clearside Biomedical receives $4M venture capital investment

Technology developed by researchers at the Georgia Institute of Technology and Emory University for delivering drugs and other therapeutics to specific locations in the eye provides the foundation for a startup company that has received a $4 million venture capital investment.

6 Jan 2012

Celtaxsys announces acquisition of CTX-4430 from Estrellita

Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.

6 Jan 2012

Sycamore Ventures announces acquisition of Trunk Health Products

Sycamore Ventures announced today that the company has acquired Trunk Health Products. Trunk Health Products resells and markets health and nutrition products through wholesale and retail outlets.

6 Jan 2012

Essilor signs five new partnership agreements in North Africa, Latin America

Essilor has further expanded its presence in fast-growing markets by signing five new partnership agreements in North Africa and Latin America.

6 Jan 2012

CLC Bio reports 30% increase in software sales in 2011

Today, CLC bio is pleased to announce that the positive growth rates of recent years have continued in 2011 with a 30% increase in software sales and a growth in operating profit of more than 50% compared to 2010.

5 Jan 2012

Midatech raises £6.3M through private investment round

Midatech Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, announced today it has raised £6.3 million through a private investment round.

5 Jan 2012

Probiodrug secures EUR 15M for clinical development of PQ912

Probiodrug AG today announced it has secured EUR 15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The lead compound, PQ912, its first QC inhibitor, is in clinical development for the treatment of Alzheimer's disease.

5 Jan 2012